2021 annual meeting

The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond

Oct. 15, 2021, 7:30 p.m. (US EDT) | Oct. 16, 2021, 7:30 a.m. (Beijing)

Live on Zoom, Free for Everyone

Login to view recordings

Overview

In June 1986, FDA approved the first antibody drug in the US — muromonab-CD3 (Orthoclone OKT3). OKT3 comprises a murine monoclonal antibody against CD3 and it is used as an immunosuppressant for the treatment of acute transplant rejection. Since then, major technological advances have made the discovery and development of therapeutic antibodies much quicker and more efficient. In the next 35 years, more and more therapeutic antibodies were approved. In April 2021, FDA approved the 100th therapeutic antibody. The approval of the 100th therapeutic antibody marked a new journey for the global antibody drug industry.

Five years ago, also in April, more than 20 professionals in the field of therapeutic antibody gathered in Boston and established the Chinese Antibody Society, a nonprofit professional organization with the mission of building a platform that facilitates the communication and collaboration of the global community in the discovery, development, manufacturing, and commercialization of antibody-based products. From that day, the Chinese Antibody Society set off its own journey. In the past five years, the Chinese Antibody Society has grown exponentially. At the time when the Chinese Antibody Society turned to 5 years old, the Chinese Antibody Society has more than 2500 registered members, has its own peer-reviewed journal Antibody Therapeutics, has held more than 40 webinars and numerous on-site events. The annual conference of the Chinese Antibody Society has also become one of the most influential conference in the therapeutic antibody field.

Standing at the milestone of the approval of the 100th therapeutic antibody, the early approved antibody products are primarily in the form of traditional IgG antibodies. In recent years, more and more non-traditional antibody formats have emerged, including bispecific antibodies, trispecific antibodies, antibody-conjugated drugs (ADC), and some complex antibody drugs in various formats such as antibody + cell, antibody + nucleic acid, antibody + small molecule, antibody + protein/peptide, etc. It is expected to the therapeutic antibody field will soon enter the new era of AntibodyPlusTM integration. The AntibodyPlusTM integration is a brand-new concept recently proposed by the Chinese Antibody Society. We firmly believe that the integration of antibody with some other therapeutic modalities is the trend in next 5~10 years.

In view of the new trend in this field, Chinese Antibody Society is now pleased to hold the 2021 Annual Conference – “The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond” in October 2021. The annual conference will be held online via Zoom and free for registration to the public. In our two half-day events, speakers from both industry and academia will share their insights in diverse topics of antibody-based therapeutics and discuss the new trend AntibodyPlusTM integration. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in antibody-based drug development. We have invited distinguished guest speakers in biopharma industry and academia specializing in the field of therapeutic antibody. Online LIVE Q & A sessions will be included after every presentation. We sincerely invite you to join us online at
(1) Oct 15, 2021 evening starting at 7: 30 PM (US EDT)/Oct 16, 2021 morning starting at 7: 30 AM (Beijing Time); and
(2) Oct 16, 2021 evening starting at 7: 40 PM (US EDT)/Oct 17, 2021 morning starting at 7: 40 AM (Beijing Time).

Sponsors

Title

Diamond

Sapphire

Emerald

Speakers

Hover above speaker cards to read bio

bio

Mitchell Ho, Ph.D.

CAS Board Member, Senior Investigator, NIH

bio

Michael Yu, Ph.D.

CAS Board Director, CEO, Innovent Biologics

bio

Fubao Wang, Ph.D.

CAS Board Member, SVP, AskLepios BioPharma

bio

Zhaohui Zhou, Ph.D.

Professor, Northeastern University

bio

Frederick W. Alt, Ph.D.

Professor, Harvard Medical School

bio

Lianshan Zhang

President, Hengrui

bio

Mark Chiu

President, Tavotek Bio Therapeutics

bio

Shouye Wang, Ph.D.

CAS Founder, Board Member, CAS

bio

Paul Carter, Ph.D.

President, The Antibody Society

bio

Zhidan Tu, Ph.D.

President, CAS

bio

Gary J. Nabel, Ph.D.

President, CEO, ModeX Therapeutics

bio

Jinbo Xu, Ph.D.

Professor, Toyota Technological Institute

bio

Pin Wang, Ph.D.

CSO, Simcere

bio

Daotian Fu, Ph.D.

CAS Board Member, President, RemeGen

bio

Jingsong Wang, Ph.D.

CEO, Harbour BioMed

bio

Hongtao Lu, Ph.D.

CSO, Elpiscience Biopharma

bio

Aimin Hui

Executive President, Fosun Pharma

bio

Jianmin Fang

CEO, RemeGen

bio

Li Chen

Director, GenScript ProBio

bio

Thomas Pillow

Principal Scientist, Genentech

bio

Dehua Pei

Professor, OSU

bio

Changshou Gao

CTO, Innovent Biologics

bio

Kai Wucherpfennig, Ph.D.

Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute

bio

Peter OCallaghan

Principle Scientist, Lonza

bio

Chris Chen, Ph.D.

CEO, WuXi Biologics

Agenda

Starts at 10/15/2021 7:30 p.m. (US EDT) | 10/16/2021 7:30 a.m. (Beijing)

Hover to view abstract

10/15/2021 7:30 p.m. EDT

Opening Remarks

Mitchell Ho, Ph.D., CAS Board Member, Senior Investigator, NIH

10/15/2021 7:45 p.m. EDT

Review of CAS

Zhidan Tu, Ph.D., President, CAS

10/15/2021 8 p.m. EDT

Partner Remarks

Paul Carter, Ph.D., President, The Antibody Society

10/15/2021 8:08 p.m. EDT

Host of first day

Fubao Wang, Ph.D., CAS Board Member, SVP, AskLepios BioPharma

10/15/2021 8:10 p.m. EDT

Session 1 Next Generation Antibodies for the Treatment of Cancer and Infections

Gary J. Nabel, Ph.D., President, CEO, ModeX Therapeutics

10/15/2021 8:40 p.m. EDT

Session 1 Targeting the CD161 CLEC2D Pathway for Cancer Immunotherapy

Kai Wucherpfennig, Ph.D., Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute

10/15/2021 9:10 p.m. EDT

Session 1 Improving Expression of Complex Proteins with a Toolbox Approach

Peter OCallaghan, Principle Scientist, Lonza

10/15/2021 10 p.m. EDT

Session 2 Getting CAR T Cells to Work on Solid Tumors

Mitchell Ho, Ph.D., CAS Board Member, Senior Investigator, NIH

10/15/2021 10:30 p.m. EDT

Session 2 Developing Covid19 Neutralizing Mabs at the Speed of Light

Chris Chen, Ph.D., CEO, WuXi Biologics

10/15/2021 11 p.m. EDT

Panel Antibody Plus

Zhaohui Zhou, Ph.D., Professor, Northeastern University

10/16/2021 7:40 p.m. EDT

Opening Remark

Michael Yu, Ph.D., CAS Board Director, CEO, Innovent Biologics

10/16/2021 7:55 p.m. EDT

Opening Remark

Shouye Wang, Ph.D., CAS Founder, Board Member, CAS

10/16/2021 8:08 p.m. EDT

Host of second day

Daotian Fu, Ph.D., CAS Board Member, President, RemeGen

10/16/2021 8:10 p.m. EDT

Session 1 Chromatin Loop Extrusion Mediated Antibody Repertoire Diversification

Frederick W. Alt, Ph.D., Professor, Harvard Medical School

10/16/2021 8:40 p.m. EDT

Session 1 Engineering T Cells for Cancer Immunotherapy

Pin Wang, Ph.D., CSO, Simcere

10/16/2021 9:10 p.m. EDT

Session 1 Accelerated COVID19 Neutralizing Antibody Discovery by Integrated Multispecific Antibody Engineering Platform

Li Chen, Director, GenScript ProBio

10/16/2021 10 p.m. EDT

Session 2 Creating an Immune Favorable Tumor Microenvironment for Tumor Immunotherapy

Hongtao Lu, Ph.D., CSO, Elpiscience Biopharma

10/16/2021 10:30 p.m. EDT

Session 2 Protein Structure Prediction by Deep Learning

Jinbo Xu, Ph.D., Professor, Toyota Technological Institute

10/16/2021 11 p.m. EDT

Panel Novel technologies in driving the development of next generation antibody and biologic therapeutics

Jingsong Wang, Ph.D., CEO, Harbour BioMed

10/17/2021 12:05 a.m. EDT

Closing Remark

Daotian Fu, Ph.D., CAS Board Member, President, RemeGen

FAQ of Meeting Registration

If you have any questions, feel free to reach out to us
This web app is a Python Django project independently coded (frontend+backend+deployment on AWS) by Xin Yu (Github, LinkedIn) in her volunteer capacity at the Chinese Antibody Society. Contents are maintained by CAS IT team. If you're interested in participating in the future development of this web app, please submit a volunteer application and request an interview with the IT team. We require a minimum of 2 years experience as a Django developer. © Chinese Antibody Society 2021. All Rights Reserved. Legal Disclaimer
Icon